Cholestatic liver diseases: An era of emerging therapies

Hrishikesh Samant, Wuttiporn Manatsathit, David Dies, Hosein Shokouh-Amiri, Gazi Zibari, Moheb Boktor, Jonathan Steve Alexander

Research output: Contribution to journalShort survey

Abstract

Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease. Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid (UDCA), the current standard treatment for cholestatic liver disease. Important novel treatment targets now also include nuclear receptors involved in bile acid (BA) homoeostasis like farnesoid X receptor and G proteincoupled receptors e.g., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5". Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA. In this review, we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.

Original languageEnglish (US)
Pages (from-to)1571-1581
Number of pages11
JournalWorld Journal of Clinical Cases
Volume7
Issue number13
DOIs
StatePublished - Jul 1 2019
Externally publishedYes

Fingerprint

Liver Diseases
Bile Acids and Salts
Therapeutics
Ursodeoxycholic Acid
Fibroblast Growth Factors
Cholestasis
Cytoplasmic and Nuclear Receptors
G-Protein-Coupled Receptors
Bile
Homeostasis
Chronic Disease
Liver
Pharmaceutical Preparations

Keywords

  • Bile acids
  • Cholestatic liver disease
  • Drug therapy
  • Nuclear receptor agonists

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Samant, H., Manatsathit, W., Dies, D., Shokouh-Amiri, H., Zibari, G., Boktor, M., & Alexander, J. S. (2019). Cholestatic liver diseases: An era of emerging therapies. World Journal of Clinical Cases, 7(13), 1571-1581. https://doi.org/10.12998/wjcc.v7.i13.1571

Cholestatic liver diseases : An era of emerging therapies. / Samant, Hrishikesh; Manatsathit, Wuttiporn; Dies, David; Shokouh-Amiri, Hosein; Zibari, Gazi; Boktor, Moheb; Alexander, Jonathan Steve.

In: World Journal of Clinical Cases, Vol. 7, No. 13, 01.07.2019, p. 1571-1581.

Research output: Contribution to journalShort survey

Samant, H, Manatsathit, W, Dies, D, Shokouh-Amiri, H, Zibari, G, Boktor, M & Alexander, JS 2019, 'Cholestatic liver diseases: An era of emerging therapies', World Journal of Clinical Cases, vol. 7, no. 13, pp. 1571-1581. https://doi.org/10.12998/wjcc.v7.i13.1571
Samant H, Manatsathit W, Dies D, Shokouh-Amiri H, Zibari G, Boktor M et al. Cholestatic liver diseases: An era of emerging therapies. World Journal of Clinical Cases. 2019 Jul 1;7(13):1571-1581. https://doi.org/10.12998/wjcc.v7.i13.1571
Samant, Hrishikesh ; Manatsathit, Wuttiporn ; Dies, David ; Shokouh-Amiri, Hosein ; Zibari, Gazi ; Boktor, Moheb ; Alexander, Jonathan Steve. / Cholestatic liver diseases : An era of emerging therapies. In: World Journal of Clinical Cases. 2019 ; Vol. 7, No. 13. pp. 1571-1581.
@article{8aa19b78855949798d6f491c19b8b345,
title = "Cholestatic liver diseases: An era of emerging therapies",
abstract = "Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease. Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid (UDCA), the current standard treatment for cholestatic liver disease. Important novel treatment targets now also include nuclear receptors involved in bile acid (BA) homoeostasis like farnesoid X receptor and G proteincoupled receptors e.g., the G-protein-coupled BA receptor {"}transmembrane G coupled receptor 5{"}. Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA. In this review, we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.",
keywords = "Bile acids, Cholestatic liver disease, Drug therapy, Nuclear receptor agonists",
author = "Hrishikesh Samant and Wuttiporn Manatsathit and David Dies and Hosein Shokouh-Amiri and Gazi Zibari and Moheb Boktor and Alexander, {Jonathan Steve}",
year = "2019",
month = "7",
day = "1",
doi = "10.12998/wjcc.v7.i13.1571",
language = "English (US)",
volume = "7",
pages = "1571--1581",
journal = "World Journal of Clinical Cases",
issn = "2307-8960",
publisher = "Baishideng Publishing Group",
number = "13",

}

TY - JOUR

T1 - Cholestatic liver diseases

T2 - An era of emerging therapies

AU - Samant, Hrishikesh

AU - Manatsathit, Wuttiporn

AU - Dies, David

AU - Shokouh-Amiri, Hosein

AU - Zibari, Gazi

AU - Boktor, Moheb

AU - Alexander, Jonathan Steve

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease. Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid (UDCA), the current standard treatment for cholestatic liver disease. Important novel treatment targets now also include nuclear receptors involved in bile acid (BA) homoeostasis like farnesoid X receptor and G proteincoupled receptors e.g., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5". Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA. In this review, we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.

AB - Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease. Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid (UDCA), the current standard treatment for cholestatic liver disease. Important novel treatment targets now also include nuclear receptors involved in bile acid (BA) homoeostasis like farnesoid X receptor and G proteincoupled receptors e.g., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5". Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA. In this review, we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.

KW - Bile acids

KW - Cholestatic liver disease

KW - Drug therapy

KW - Nuclear receptor agonists

UR - http://www.scopus.com/inward/record.url?scp=85069463078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069463078&partnerID=8YFLogxK

U2 - 10.12998/wjcc.v7.i13.1571

DO - 10.12998/wjcc.v7.i13.1571

M3 - Short survey

C2 - 31367616

AN - SCOPUS:85069463078

VL - 7

SP - 1571

EP - 1581

JO - World Journal of Clinical Cases

JF - World Journal of Clinical Cases

SN - 2307-8960

IS - 13

ER -